Geron Corporation (GERN)
| Market Cap | 980.58M +10.8% |
| Revenue (ttm) | 183.88M +138.8% |
| Net Income | -83.50M |
| EPS | -0.13 |
| Shares Out | 640.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,325,187 |
| Open | 1.500 |
| Previous Close | 1.500 |
| Day's Range | 1.500 - 1.590 |
| 52-Week Range | 1.040 - 2.010 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 2.17 (+41.83%) |
| Earnings Date | May 6, 2026 |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for GERN stock is "Hold." The 12-month stock price target is $2.17, which is an increase of 41.83% from the latest price.
News
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock ...
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a ...
Geron Transcript: 25th Annual Needham Virtual Healthcare Conference
Imetelstat, a first-in-class telomerase inhibitor, is driving growth in low-risk MDS with $184M revenue in 2025 and guidance of $220–$240M for 2026. Focus is on expanding second-line use, physician education, and advancing a pivotal myelofibrosis trial.
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial ...
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to...
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos a...
Geron Transcript: Barclays 28th Annual Global Healthcare Conference
RYTELO achieved strong initial sales and is positioned for 20–30% growth in 2026, driven by second-line MDS market expansion and a focus on community adoption. The drug's unique mechanism and positive long-term data support confidence in further uptake, while a pivotal MF trial could unlock additional value.
Geron Transcript: TD Cowen 46th Annual Health Care Conference
RYTELO achieved $184 million in first-year sales, with 2025 guidance of $220–$240 million, driven by strategic focus on second-line MDS patients and refined commercial execution. EMA approval and ongoing ISTs support international expansion and broader clinical applications.
Geron Earnings Call Transcript: Q4 2025
RYTELO delivered $184M in 2025 net revenue, with strong Q4 growth and expanding prescriber base. 2026 guidance targets $220M-$240M revenue and reduced expenses, focusing on second-line, lower-risk MDS patients and continued commercial execution.
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, with...
Geron Plans to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Top 3 Health Care Stocks That May Collapse This Quarter
As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Geron Corporation Provides 2026 Financial Guidance
2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and st...
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) ...
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl...
Geron Transcript: Evercore ISI 8th Annual HealthCONx Conference
RYTELO's commercial uptake is improving as focus shifts to second-line MDS patients, supported by strong clinical data and updated guidelines. Physician engagement and targeted spending are driving growth, while the fully enrolled IMpactMF trial could expand the addressable market in coming years.
Geron Transcript: Stifel 2025 Healthcare Conference
RYTELO's commercial growth has been slower than expected due to late-line use and limited US physician experience, but strategic initiatives are underway to shift adoption to earlier lines and expand market penetration. Updated guidelines and competitive dynamics are expected to support growth, with 2026 targeted as a pivotal year.
Geron Earnings Call Transcript: Q3 2025
Q3 2025 saw $47M in revenue, 15% growth in prescribing accounts, and increased new patient starts in earlier lines, though overall demand was down 3% sequentially. Focus remains on driving Rytelo adoption, operational efficiency, and preparing for 2026 growth.
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...
Geron Corporation to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it wi...
Geron Corporation Announces Executive Leadership Transitions and Appointments
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commerc...